Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer

INTRODUCTION: Cabazitaxel multiple rechallenges may be a treatment option in heavily pretreated patients with metastatic castration‐resistant prostate cancer (mCRPC) who had a good initial response to cabazitaxel and who are still fit to receive it. Our objective was to assess the efficacy and toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pobel, Cedric, Auclin, Edouard, Teyssonneau, Diego, Laguerre, Brigitte, Cancel, Mathilde, Boughalem, Elouen, Noel, Johanna, Brachet, Pierre Emmanuel, Maillet, Denis, Barthelemy, Philippe, Helissey, Carole, Thibault, Constance, Oudard, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446560/
https://www.ncbi.nlm.nih.gov/pubmed/34382352
http://dx.doi.org/10.1002/cam4.4172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446560/
https://www.ncbi.nlm.nih.gov/pubmed/34382352
http://dx.doi.org/10.1002/cam4.4172

Ejemplares similares